University of North Carolina at Chapel Hill Clinical and Translational Science Awards (UNC-CTSA)
This sponsor has funded 1 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 3255 | Finalised | Incretin-based therapies and Pancreatic Cancer risk in Medicare enrollees – new user protocol | Yes | Yes |
PAS by Risk Management Plan (RMP) requirement
University of North Carolina at Chapel Hill Clinical and Translational Science Awards (UNC-CTSA)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
University of North Carolina at Chapel Hill Clinical and Translational Science Awards (UNC-CTSA)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
University of North Carolina at Chapel Hill Clinical and Translational Science Awards (UNC-CTSA)
1 Study countries specified are the following:
- United States